This board is always looking in the rear view mirror with 20/20 hindsight....... How about a PROACTIVE view going forward.....
1. Amarin deciding to sell a GV product might advance US sales against Generics ,but at what price... lower selling prices against our known advantage in API product costs = ? profits.
2. Amarin selling GV (Generic Vascepa ) to US market cannibalizes our pricing to bring European Countries aboard ...... look at GERMANY !!! now all other countries would want
US pricing.... same situation with China,Australia, etc.
3. Fixed doze combination in US (md2119)..... Generics sell 40% of US market already with Amarin having CV approval with FDA.... Generics simply sit back a few months to study selling results of fixed doze combination and come up with blister pack or some form of combination..... they then sell to pharmacies like what they are doing now .... who promotes fixed doze combination to the US market ???? not Amarin .... we lose sales to Generics (maybe 40% or 50% or 60%....
4. KM stated that they will explore Europian market first with fixed doze to see how acceptable it would be received and what sales will amount to.... smart choice, since we have exclusivity their and in the rest of the world.... That's when you explore avenues in the US market for exclusivity ....
5. KM believes sales will be generated more in the Virtual market than sales rep's could provide at a lower cost ( stated at JPM Conference )..... maybe eliminating pharmacies selling the product and setting up direct sales to consumers ( look at what Mark Cuban ) is initiating will be our avenue to proceed.... maybe building our own manufacturing facility could be a way to go....
6. Proactive ??????
7. Supporting, giving Denner 3 seats on the board and watching what he does and how he communicates with the Shareholders would give be most enlightening.......
